DOCSLIB.ORG

Mouse Bcl2l13 Conditional Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mouse Bcl2l13 Conditional Knockout Project (CRISPR/Cas9) https://www.alphaknockout.com Mouse Bcl2l13 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Bcl2l13 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Bcl2l13 gene (NCBI Reference Sequence: NM_153516 ; Ensembl: ENSMUSG00000009112 ) is located on Mouse chromosome 6. 7 exons are identified, with the ATG start codon in exon 2 and the TAA stop codon in exon 7 (Transcript: ENSMUST00000009256). Exon 2 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Bcl2l13 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-385F20 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Exon 2 starts from about 100% of the coding region. The knockout of Exon 2 will result in frameshift of the gene. The size of intron 1 for 5'-loxP site insertion: 12098 bp, and the size of intron 2 for 3'-loxP site insertion: 14238 bp. The size of effective cKO region: ~612 bp. The cKO region does not have any other known gene. Page 1 of 7 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele gRNA region 5' gRNA region 3' 1 2 7 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Bcl2l13 Homology arm cKO region loxP site Page 2 of 7 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. No significant tandem repeat is found in the dot plot matrix. So this region is suitable for PCR screening or sequencing analysis. Overview of the GC Content Distribution Window size: 300 bp Sequence 12 Summary: Full Length(7112bp) | A(26.69% 1898) | C(21.02% 1495) | T(31.96% 2273) | G(20.33% 1446) Note: The sequence of homologous arms and cKO region is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Page 3 of 7 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN -------------------------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr6 + 120845256 120848255 3000 browser details YourSeq 264 1005 1596 3000 93.5% chr13 + 64316926 64317883 958 browser details YourSeq 263 1025 1595 3000 92.1% chr10 - 117064448 117065576 1129 browser details YourSeq 260 1015 1744 3000 83.5% chr8 + 107166843 107167433 591 browser details YourSeq 259 1023 1596 3000 87.0% chr4 + 141765416 141765765 350 browser details YourSeq 253 1050 2039 3000 84.7% chr11 - 88921639 88922421 783 browser details YourSeq 250 1025 1596 3000 90.1% chr11 - 51590428 51798550 208123 browser details YourSeq 244 1055 1596 3000 88.0% chr3 + 94934978 94935357 380 browser details YourSeq 243 1024 1595 3000 87.2% chr10 - 81211023 81211459 437 browser details YourSeq 227 1025 1596 3000 85.0% chr15 - 99000002 99000308 307 browser details YourSeq 219 1023 1590 3000 84.4% chr9 - 44893143 44893449 307 browser details YourSeq 204 1028 1596 3000 83.8% chr12 - 84298485 84298915 431 browser details YourSeq 190 1097 1596 3000 85.0% chr17 - 29196510 29196918 409 browser details YourSeq 187 1405 2052 3000 88.3% chr19 - 44541295 44541959 665 browser details YourSeq 181 1122 1596 3000 92.5% chr13 - 54901380 54902041 662 browser details YourSeq 174 1086 1595 3000 83.8% chr5 + 135292729 135293154 426 browser details YourSeq 173 1404 2072 3000 82.2% chr11 - 119361490 119361725 236 browser details YourSeq 173 944 1596 3000 83.9% chr17 + 85096963 85097181 219 browser details YourSeq 172 1112 1597 3000 90.6% chr2 - 146789656 146790278 623 browser details YourSeq 172 1409 1619 3000 91.4% chr15 + 99009278 99009944 667 Note: The 3000 bp section upstream of Exon 2 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr6 + 120848868 120851867 3000 browser details YourSeq 1341 450 2659 3000 90.0% chr6 + 133873078 133875044 1967 browser details YourSeq 1255 468 2660 3000 89.5% chr3 + 123770870 123772669 1800 browser details YourSeq 1202 455 2618 3000 88.3% chr17 - 36589187 36591012 1826 browser details YourSeq 1169 473 2659 3000 88.2% chr10 - 86773008 86774771 1764 browser details YourSeq 1099 591 2614 3000 87.7% chrX + 127091391 127440441 349051 browser details YourSeq 861 1053 2659 3000 88.7% chr2 - 52748388 52749650 1263 browser details YourSeq 829 1482 2659 3000 90.6% chrX - 36686105 36687326 1222 browser details YourSeq 814 1482 2644 3000 88.1% chr1 - 146659083 146660260 1178 browser details YourSeq 812 1483 2662 3000 88.2% chr8 + 4600031 4601138 1108 browser details YourSeq 811 1482 2660 3000 89.3% chr12 + 59254989 59256085 1097 browser details YourSeq 810 1482 2644 3000 89.1% chr2 - 89452598 89453729 1132 browser details YourSeq 809 1485 2661 3000 89.3% chr17 + 17656199 17657431 1233 browser details YourSeq 808 1488 2795 3000 87.8% chr12 - 64808125 64809382 1258 browser details YourSeq 805 1482 2658 3000 87.9% chr11 - 110123063 110124279 1217 browser details YourSeq 786 1483 2659 3000 88.5% chr14 + 73103683 73104803 1121 browser details YourSeq 782 1482 2635 3000 88.8% chr2 + 111601506 111602686 1181 browser details YourSeq 779 1482 2660 3000 87.0% chr3 - 103847525 103848675 1151 browser details YourSeq 778 1489 2659 3000 88.3% chr1 - 174433476 174434727 1252 browser details YourSeq 769 1482 2661 3000 88.3% chr13 + 36253036 36254142 1107 Note: The 3000 bp section downstream of Exon 2 is BLAT searched against the genome. No significant similarity is found. Page 4 of 7 https://www.alphaknockout.com Gene and protein information: Bcl2l13 BCL2-like 13 (apoptosis facilitator) [ Mus musculus (house mouse) ] Gene ID: 94044, updated on 10-Oct-2019 Gene summary Official Symbol Bcl2l13 provided by MGI Official Full Name BCL2-like 13 (apoptosis facilitator) provided by MGI Primary source MGI:MGI:2136959 See related Ensembl:ENSMUSG00000009112 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as Mil1; Mil-1; BCL-RAMBO; E430016C20Rik Expression Ubiquitous expression in heart adult (RPKM 9.6), subcutaneous fat pad adult (RPKM 9.3) and 28 other tissues See more Orthologs human all Genomic context Location: 6 F1; 6 57.01 cM See Bcl2l13 in Genome Data Viewer Exon count: 7 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) 6 NC_000072.6 (120836206..120892842) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 6 NC_000072.5 (120786248..120842860) Chromosome 6 - NC_000072.6 Page 5 of 7 https://www.alphaknockout.com Transcript information: This gene has 4 transcripts Gene: Bcl2l13 ENSMUSG00000009112 Description BCL2-like 13 (apoptosis facilitator) [Source:MGI Symbol;Acc:MGI:2136959] Gene Synonyms BCL-RAMBO, E430016C20Rik, Mil-1, Mil1 Location Chromosome 6: 120,836,212-120,892,842 forward strand. GRCm38:CM000999.2 About this gene This gene has 4 transcripts (splice variants), 205 orthologues and is a member of 1 Ensembl protein family. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Bcl2l13-201 ENSMUST00000009256.3 6925 434aa ENSMUSP00000009256.2 Protein coding CCDS20485 P59017 TSL:1 GENCODE basic APPRIS P1 Bcl2l13-202 ENSMUST00000203037.2 408 75aa ENSMUSP00000145390.1 Protein coding - A0A0N4SW63 CDS 3' incomplete TSL:5 Bcl2l13-203 ENSMUST00000203584.2 349 51aa ENSMUSP00000145341.1 Protein coding - A0A0N4SW24 CDS 3' incomplete TSL:2 Bcl2l13-204 ENSMUST00000204004.1 2710 No protein - Retained intron - - TSL:1 76.63 kb Forward strand 120.84Mb 120.86Mb 120.88Mb 120.90Mb Genes (Comprehensive set... Bcl2l13-204 >retained intron Bcl2l13-203 >protein coding Bcl2l13-202 >protein coding Bcl2l13-201 >protein coding Contigs AC084273.20 > < AC083894.21 Genes < Bid-204nonsense mediated decay (Comprehensive set... < Bid-205retained intron < Bid-201protein coding < Bid-203protein coding Regulatory Build 120.84Mb 120.86Mb 120.88Mb 120.90Mb Reverse strand 76.63 kb Regulation Legend CTCF Enhancer Open Chromatin Promoter Promoter Flank Transcription Factor Binding Site Gene Legend Protein Coding Ensembl protein coding merged Ensembl/Havana Non-Protein Coding processed transcript Page 6 of 7 https://www.alphaknockout.com Transcript: ENSMUST00000009256 56.60 kb Forward strand Bcl2l13-201 >protein coding ENSMUSP00000009... Transmembrane heli... MobiDB lite Low complexity (Seg) Coiled-coils (Ncoils) Superfamily Blc2-like superfamily Pfam Blc2 family PROSITE profiles Bcl2-like PANTHER Bcl-2-like protein 13 Gene3D Blc2-like superfamily All sequence SNPs/i... Sequence variants (dbSNP and all other sources) Variant Legend missense variant synonymous variant Scale bar 0 40 80 120 160 200 240 280 320 360 434 We wish to acknowledge the following valuable scientific information resources: Ensembl, MGI, NCBI, UCSC. Page 7 of 7.
Load more

Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Receptor-Mediated Mitophagy Accepted21march2016
    King’s Research Portal DOI: 10.1016/j.yjmcc.2016.03.010 Document Version Peer reviewed version Link to publication record in King's Research Portal Citation for published version (APA): Yamaguchi, O., Murakawa, T., Nishida, K., & Otsu, K. (2016). Receptor-mediated mitophagy. Journal of Molecular and Cellular Cardiology, 95, 50-56. [95]. https://doi.org/10.1016/j.yjmcc.2016.03.010 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association Between BMI and Adult-Onset Non- Atopic
    Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association between BMI and Adult-Onset Non- Atopic Asthma Ayoung Jeong 1,2, Medea Imboden 1,2, Akram Ghantous 3, Alexei Novoloaca 3, Anne-Elie Carsin 4,5,6, Manolis Kogevinas 4,5,6, Christian Schindler 1,2, Gianfranco Lovison 7, Zdenko Herceg 3, Cyrille Cuenin 3, Roel Vermeulen 8, Deborah Jarvis 9, André F. S. Amaral 9, Florian Kronenberg 10, Paolo Vineis 11,12 and Nicole Probst-Hensch 1,2,* 1 Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; [email protected] (A.J.); [email protected] (M.I.); [email protected] (C.S.) 2 Department of Public Health, University of Basel, 4001 Basel, Switzerland 3 International Agency for Research on Cancer, 69372 Lyon, France; [email protected] (A.G.); [email protected] (A.N.); [email protected] (Z.H.); [email protected] (C.C.) 4 ISGlobal, Barcelona Institute for Global Health, 08003 Barcelona, Spain; [email protected] (A.-E.C.); [email protected] (M.K.) 5 Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain 6 CIBER Epidemiología y Salud Pública (CIBERESP), 08005 Barcelona, Spain 7 Department of Economics, Business and Statistics, University of Palermo, 90128 Palermo, Italy; [email protected] 8 Environmental Epidemiology Division, Utrecht University, Institute for Risk Assessment Sciences, 3584CM Utrecht, Netherlands; [email protected] 9 Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College, SW3 6LR London, UK; [email protected] (D.J.); [email protected] (A.F.S.A.) 10 Division of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; [email protected] 11 MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, W2 1PG London, UK; [email protected] 12 Italian Institute for Genomic Medicine (IIGM), 10126 Turin, Italy * Correspondence: [email protected]; Tel.: +41-61-284-8378 Int.
    [Show full text]
  • Supplementary Material and Methods
    Supplementary material and methods Generation of cultured human epidermal sheets Normal human epidermal keratinocytes were isolated from human breast skin. Keratinocytes were grown on a feeder layer of irradiated human fibroblasts pre-seeded at 4000 cells /cm² in keratinocyte culture medium (KCM) containing a mix of 3:1 DMEM and HAM’s F12 (Invitrogen, Carlsbad, USA), supplemented with 10% FCS, 10ng/ml epidermal growth factor (EGF; R&D systems, Minneapolis, MN, USA), 0.12 IU/ml insulin (Lilly, Saint- Cloud, France), 0.4 mg/ml hydrocortisone (UpJohn, St Quentin en Yvelelines, France) , 5 mg/ml triiodo-L- thyronine (Sigma, St Quentin Fallavier, France), 24.3 mg/ml adenine (Sigma), isoproterenol (Isuprel, Hospira France, Meudon, France) and antibiotics (20 mg/ml gentamicin (Phanpharma, Fougères, France), 100 IU/ml penicillin (Phanpharma), and 1 mg/ml amphotericin B (Phanpharma)). The medium was changed every two days. NHEK were then cultured over a period of 13 days according to the protocol currently used at the Bank of Tissues and Cells for the generation of clinical grade epidermal sheets used for the treatment of severe extended burns (Ref). When needed, cells were harvested with trypsin-EDTA 0.05% (Thermo Fisher Scientific, Waltham, MA, USA) and collected for analysis. Clonogenic assay Keratinocytes were seeded on a feeder layer of irradiated fibroblasts, at a clonal density of 10-20 cells/cm² and cultivated for 10 to 14 days. Three flasks per tested condition were fixed and colored in a single 30 mns step using rhodamine B (Sigma) diluted at 0.01 g/ml in 4% paraformaldehyde. In each tested condition, cells from 3 other flasks were numerated after detachment by trypsin treatment.
    [Show full text]
  • Alterations of the Interactome of Bcl-2 Proteins in Breast Cancer at the Transcriptional, Mutational and Structural Level
    RESEARCH ARTICLE Alterations of the interactome of Bcl-2 proteins in breast cancer at the transcriptional, mutational and structural level Simon Mathis Kønig1, Vendela Rissler1, Thilde Terkelsen1, Matteo Lambrughi1, 1,2 Elena PapaleoID * 1 Computational Biology Laboratory, Danish Cancer Society Research Center, Copenhagen, Denmark, a1111111111 2 Translational Disease Systems Biology, Faculty of Health and Medical Sciences, Novo Nordisk Foundation Center for Protein Research University of Copenhagen, Copenhagen, Denmark a1111111111 a1111111111 * [email protected] a1111111111 a1111111111 Abstract Apoptosis is an essential defensive mechanism against tumorigenesis. Proteins of the B- OPEN ACCESS cell lymphoma-2 (Bcl-2) family regulate programmed cell death by the mitochondrial apopto- sis pathway. In response to intracellular stress, the apoptotic balance is governed by inter- Citation: Kønig SM, Rissler V, Terkelsen T, Lambrughi M, Papaleo E (2019) Alterations of the actions of three distinct subgroups of proteins; the activator/sensitizer BH3 (Bcl-2 homology interactome of Bcl-2 proteins in breast cancer at 3)-only proteins, the pro-survival, and the pro-apoptotic executioner proteins. Changes in the transcriptional, mutational and structural level. expression levels, stability, and functional impairment of pro-survival proteins can lead to an PLoS Comput Biol 15(12): e1007485. https://doi. imbalance in tissue homeostasis. Their overexpression or hyperactivation can result in org/10.1371/journal.pcbi.1007485 oncogenic effects. Pro-survival Bcl-2 family members carry out their function by binding the Editor: Igor N. Berezovsky, A�STAR Singapore, BH3 short linear motif of pro-apoptotic proteins in a modular way, creating a complex net- SINGAPORE work of protein-protein interactions. Their dysfunction enables cancer cells to evade cell Received: July 8, 2019 death.
    [Show full text]
  • Engineered Type 1 Regulatory T Cells Designed for Clinical Use Kill Primary
    ARTICLE Acute Myeloid Leukemia Engineered type 1 regulatory T cells designed Ferrata Storti Foundation for clinical use kill primary pediatric acute myeloid leukemia cells Brandon Cieniewicz,1* Molly Javier Uyeda,1,2* Ping (Pauline) Chen,1 Ece Canan Sayitoglu,1 Jeffrey Mao-Hwa Liu,1 Grazia Andolfi,3 Katharine Greenthal,1 Alice Bertaina,1,4 Silvia Gregori,3 Rosa Bacchetta,1,4 Norman James Lacayo,1 Alma-Martina Cepika1,4# and Maria Grazia Roncarolo1,2,4# Haematologica 2021 Volume 106(10):2588-2597 1Department of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, USA; 2Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, USA; 3San Raffaele Telethon Institute for Gene Therapy, Milan, Italy and 4Center for Definitive and Curative Medicine, Stanford School of Medicine, Stanford, CA, USA *BC and MJU contributed equally as co-first authors #AMC and MGR contributed equally as co-senior authors ABSTRACT ype 1 regulatory (Tr1) T cells induced by enforced expression of interleukin-10 (LV-10) are being developed as a novel treatment for Tchemotherapy-resistant myeloid leukemias. In vivo, LV-10 cells do not cause graft-versus-host disease while mediating graft-versus-leukemia effect against adult acute myeloid leukemia (AML). Since pediatric AML (pAML) and adult AML are different on a genetic and epigenetic level, we investigate herein whether LV-10 cells also efficiently kill pAML cells. We show that the majority of primary pAML are killed by LV-10 cells, with different levels of sensitivity to killing. Transcriptionally, pAML sensitive to LV-10 killing expressed a myeloid maturation signature.
    [Show full text]
  • Proteomic Signatures of Brain Regions Affected by Tau Pathology in Early and Late Stages of Alzheimer's Disease
    Neurobiology of Disease 130 (2019) 104509 Contents lists available at ScienceDirect Neurobiology of Disease journal homepage: www.elsevier.com/locate/ynbdi Proteomic signatures of brain regions affected by tau pathology in early and T late stages of Alzheimer's disease Clarissa Ferolla Mendonçaa,b, Magdalena Kurasc, Fábio César Sousa Nogueiraa,d, Indira Plác, Tibor Hortobágyie,f,g, László Csibae,h, Miklós Palkovitsi, Éva Renneri, Péter Dömej,k, ⁎ ⁎ György Marko-Vargac, Gilberto B. Domonta, , Melinda Rezelic, a Proteomics Unit, Department of Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil b Gladstone Institute of Neurological Disease, San Francisco, USA c Division of Clinical Protein Science & Imaging, Department of Clinical Sciences (Lund) and Department of Biomedical Engineering, Lund University, Lund, Sweden d Laboratory of Proteomics, LADETEC, Institute of Chemistry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil e MTA-DE Cerebrovascular and Neurodegenerative Research Group, University of Debrecen, Debrecen, Hungary f Institute of Pathology, Faculty of Medicine, University of Szeged, Szeged, Hungary g Centre for Age-Related Medicine, SESAM, Stavanger University Hospital, Stavanger, Norway h Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary i SE-NAP – Human Brain Tissue Bank Microdissection Laboratory, Semmelweis University, Budapest, Hungary j Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary k National Institute of Psychiatry and Addictions, Nyírő Gyula Hospital, Budapest, Hungary ARTICLE INFO ABSTRACT Keywords: Background: Alzheimer's disease (AD) is the most common neurodegenerative disorder. Depositions of amyloid β Alzheimer's disease peptide (Aβ) and tau protein are among the major pathological hallmarks of AD. Aβ and tau burden follows Proteomics predictable spatial patterns during the progression of AD.
    [Show full text]
  • Database and Bioinformatic Analysis of BCL-2 Family Proteins and BH3-Only Proteins Abdel Aouacheria, Vincent Navratil, Christophe Combet
    Database and Bioinformatic Analysis of BCL-2 Family Proteins and BH3-Only Proteins Abdel Aouacheria, Vincent Navratil, Christophe Combet To cite this version: Abdel Aouacheria, Vincent Navratil, Christophe Combet. Database and Bioinformatic Analysis of BCL-2 Family Proteins and BH3-Only Proteins. Gavathiotis E. BCL-2 Family Proteins. Methods in Molecular Biology, 1877, Springer Nature, pp.23-43, 2019, Methods in Molecular Biology, 978-1-4939- 8860-0. 10.1007/978-1-4939-8861-7_2. hal-02347884 HAL Id: hal-02347884 https://hal.archives-ouvertes.fr/hal-02347884 Submitted on 5 Nov 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Copyright Database and bioinformatic analysis of BCL-2 family proteins and BH3-only proteins Abdel Aouacheria 1,*, Vincent Navratil 2 and Christophe Combet 3 1 ISEM, Institut des Sciences de l’Evolution de Montpellier, Université de Montpellier, UMR 5554, CNRS, IRD, EPHE, Place Eugène Bataillon, 34095 Montpellier, France 2 PRABI, Rhône Alpes Bioinformatics Center, UCBL, Lyon1, Université de Lyon, Lyon, France. 3 Centre de Recherche en Cancérologie de Lyon, UMR Inserm U1052, CNRS 5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France.
    [Show full text]
  • Anti-VEGF Drugs Influence Epigenetic Regulation and AMD-Specific
    cells Article Anti-VEGF Drugs Influence Epigenetic Regulation and AMD-Specific Molecular Markers in ARPE-19 Cells Mohamed A. Hamid 1,2,† , M. Tarek Moustafa 1,2,† , Sonali Nashine 1, Rodrigo Donato Costa 1,3 , Kevin Schneider 1, Shari R. Atilano 1 , Baruch D. Kuppermann 1,4 and M. Cristina Kenney 1,5,* 1 Gavin Herbert Eye Institute, University of California Irvine, Irvine, CA 92697, USA; [email protected] (M.A.H.); [email protected] (M.T.M.); [email protected] (S.N.); [email protected] (R.D.C.); [email protected] (K.S.); [email protected] (S.R.A.); [email protected] (B.D.K.) 2 Ophthalmology Department, Faculty of Medicine, Minia University, Minia 61111, Egypt 3 Instituto Donato Oftalmologia, PoVos de Caldas, MG 37701-528, Brazil 4 Department of Biomedical Engineering, University of California Irvine, Irvine, CA 92697, USA 5 Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, CA 92697, USA * Correspondence: [email protected]; Tel.: +1-949-824-7603 † Both authors contributed equally. Abstract: Our study assesses the effects of anti-VEGF (Vascular Endothelial Growth Factor) drugs and Trichostatin A (TSA), an inhibitor of histone deacetylase (HDAC) activity, on cultured ARPE-19 (Adult Retinal Pigment Epithelial-19) cells that are immortalized human retinal pigment epithelial cells. ARPE-19 cells were treated with the following anti-VEGF drugs: aflibercept, ranibizumab, or bevacizumab at 1× and 2× concentrations of the clinical intravitreal dose (12.5 µL/mL and 25 µL/mL, Citation: Hamid, M.A.; Moustafa, respectively) and analyzed for transcription profiles of genes associated with the pathogenesis M.T.; Nashine, S.; Costa, R.D.; age-related macular degeneration (AMD).
    [Show full text]
  • Alterations of the Pro-Survival Bcl-2 Protein Interactome in Breast Cancer
    bioRxiv preprint doi: https://doi.org/10.1101/695379; this version posted July 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Alterations of the pro-survival Bcl-2 protein interactome in 2 breast cancer at the transcriptional, mutational and 3 structural level 4 5 Simon Mathis Kønig1, Vendela Rissler1, Thilde Terkelsen1, Matteo Lambrughi1, Elena 6 Papaleo1,2 * 7 1Computational Biology Laboratory, Danish Cancer Society Research Center, 8 Strandboulevarden 49, 2100, Copenhagen 9 10 2Translational Disease Systems Biology, Faculty of Health and Medical Sciences, Novo 11 Nordisk Foundation Center for Protein Research University of Copenhagen, Copenhagen, 12 Denmark 13 14 Abstract 15 16 Apoptosis is an essential defensive mechanism against tumorigenesis. Proteins of the B-cell 17 lymphoma-2 (Bcl-2) family regulates programmed cell death by the mitochondrial apoptosis 18 pathway. In response to intracellular stresses, the apoptotic balance is governed by interactions 19 of three distinct subgroups of proteins; the activator/sensitizer BH3 (Bcl-2 homology 3)-only 20 proteins, the pro-survival, and the pro-apoptotic executioner proteins. Changes in expression 21 levels, stability, and functional impairment of pro-survival proteins can lead to an imbalance 22 in tissue homeostasis. Their overexpression or hyperactivation can result in oncogenic effects. 23 Pro-survival Bcl-2 family members carry out their function by binding the BH3 short linear 24 motif of pro-apoptotic proteins in a modular way, creating a complex network of protein- 25 protein interactions.
    [Show full text]
  • Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: a Focus on the Mode of Drug Resistance Shih-Hsiang Chen
    Pediatrics and Neonatology (2015) 56, 287e293 Available online at www.sciencedirect.com ScienceDirect journal homepage: http://www.pediatr-neonatol.com REVIEW ARTICLE Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance Shih-Hsiang Chen Division of Hematology/Oncology, Department of Pediatrics, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, 5 Fu-Shin Street, Kwei-Shan 333, Taoyuan, Taiwan Received Apr 24, 2014; received in revised form Aug 28, 2014; accepted Oct 6, 2014 Available online 23 December 2014 Key Words Asparaginase is one of the most important chemotherapeutic agents against pediatric acute acute lymphoblastic lymphoblastic leukemia (ALL), the most common form of childhood cancer. The therapeutic leukemia; efficacy (e.g., chemoresistance) and adverse effects of asparaginase (e.g., hypersensivity asparaginase; and pancreatitis) have been investigated over the past four decades. It was suggested early chemotherapy; on that leukemic cells are resistant to asparaginase because of their increased asparagine syn- children; thetase activity. Afterward, other mechanisms associated with asparaginase resistance were resistance reported. Not only leukemic cells but also patients themselves may play a role in causing as- paraginase resistance, which has been associated with unfavorable outcome in children with ALL. This article will briefly review asparaginase therapy in children with ALL and comprehen- sively analyze recent reports on the potential mechanisms of asparaginase resistance. Copyright ª 2015, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved. 1. Introduction Taiwan Childhood Cancer Foundation, there are about 130e140 newly diagnosed ALL children (younger than Acute lymphoblastic leukemia (ALL) is the most common 18 years), accounting for 25% of all childhood cancers in cancer in children.
    [Show full text]